Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Albuvirtide plus Lopinavir-ritonavir in HIV-1-infected adults failed standard first-line ART regimen

Trial Profile

Efficacy and safety of Albuvirtide plus Lopinavir-ritonavir in HIV-1-infected adults failed standard first-line ART regimen

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albuvirtide (Primary) ; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TALENT
  • Sponsors Frontier Biotechnologies
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Aug 2016 Status changed from recruiting to completed.
    • 06 Jun 2016 According to Frontier Biotechnologies media release, and NDA is to be submitted to China FDA in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top